Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

KalVista Pharmaceuticals, Inc. (KALV) had Revenue of $13.69M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$13.69M
Net Income	$-49.48M
Cost of Goods Sold	$1.23M
Gross Profit	$12.46M
Operating Expenses	$59.74M
Operating Income	$-46.05M
Non-Operating Income/Expense	$-1.27M
Pre-Tax Income	$-47.33M
Normalized Pre-Tax Income	$-47.33M
Income after Taxes	$-49.48M
Income from Continuous Operations	$-49.48M
Consolidated Net Income/Loss	$-49.48M
Normalized Income after Taxes	$-49.48M
EBIT	$-46.05M
EBITDA	$-46.05M
Weighted-Average Shares Outstanding (Basic)	53.88M
Weighted-Average Shares Outstanding (Diluted)	53.88M
Earnings per Share (EPS) (Basic)	$-0.92
Earnings per Share (EPS) (Diluted)	$-0.92
Balance Sheet Financials
Current Assets	$325.23M
Property, Plant, and Equipment	$3.19M
Long-Term Assets	$14.71M
Total Assets	$339.93M
Current Liabilities	$45.07M
Long-Term Debt	$139.03M
Long-Term Liabilities	$277.86M
Total Liabilities	$322.93M
Common Equity	$17.00M
Tangible Shareholders Equity	$17.00M
Shareholders Equity	$17.00M
Common Shares Outstanding	50.54M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-126.98M
Cash Flow from Investing Activities	$19.87M
Cash Flow from Financial Activities	$164.39M
Beginning Cash	$182.98M
End Cash	$244.30M
Increase/Decrease in Cash	$61.32M
Stock-Based Compensation	$12.23M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	7.22
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.89
Debt to Equity Ratio	8.18
Gross Margin	91.00%
Operating Margin	-336.33%
EBIT Margin	-336.33%
EBITDA Margin	--
Pre-Tax Profit Margin	-345.64%
Profit Margin	-361.39%
Free Cash Flow	$-129.23M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.04
Inventory Turnover	2.69
Receiveable Turnover	1.92
Days Sales in Receivables	46.81
Return on Equity	-291.09%
Return on Tangible Equity	-291.09%
Return on Assets	-14.56%
Return on Investments	-31.71%
Book Value Per Share	$0.34
Free Cash Flow per Share	$-2.40
Operating Cash Flow per Share	$-2.36

Data from Zacks Investment Research, Inc.